8-KLeadership Changes

TARGET CORP 8-K Report, Executive Changes (Oct 17, 2023)

Filed October 17, 2023For Securities:TGT

Summary

This 8-K filing from Target Corporation announces the upcoming retirement of its Executive Vice President and Chief Operating Officer (COO), John J. Mulligan. Mr. Mulligan intends to retire from his COO role in February 2024, after which he will transition to a strategic advisor position, serving as a non-executive officer until February 2025. While the material terms of this advisor agreement are still being finalized, this transition represents a significant leadership change within Target's operational management. Investors should note that Mr. Mulligan has been a key figure in Target's operations, and his departure from the COO role, though with a planned transition, will bring about a change in leadership. The company has indicated that further details regarding the specific terms of his advisory role will be disclosed upon finalization. This information is crucial for understanding the continuity of operational strategy and executive team stability.

Key Highlights

  • 1John J. Mulligan, EVP and COO, announced his intention to retire from his COO position.
  • 2Retirement from COO role is scheduled for February 2024.
  • 3Mr. Mulligan will transition to a strategic advisor role.
  • 4He will serve as a non-executive officer until February 2025 in the advisor capacity.
  • 5Material terms of the strategic advisor agreement are pending finalization and will be disclosed later.
  • 6This represents a significant executive leadership change in Target's operational management.

Frequently Asked Questions

John J. Mulligan, Executive Vice President and Chief Operating Officer (COO), has announced his intention to retire from his COO position.

Mr. Mulligan is expected to retire from his COO role in February 2024.

He will transition to a strategic advisor role and serve as a non-executive officer until February 2025.

No, the material terms of Mr. Mulligan’s strategic advisor agreement are still being finalized and will be disclosed once they have been confirmed.